Monday, 20 January 2020

The first full day of the Congress, open to Industry and Standard ticket holders, focuses on the latest in EB research – including current challenges, therapeutics, and a clinical trial update.

For any queries related to the programme, please email programme@ebworldcongress.org.

Please note: The Congress programme is updated monthly and the current version is, therefore, subject to change.

Programme overview

08:30 | WELCOME
Chairs: Jemima Mellerio & Jouni Uitto
Challenges and unmet needs – the breadth of preclinical work ongoing
Jouni Uitto
08:40 | CLASSIFICATION
Chair: Jo-David Fine
EB classification and updates from the 2019 classification meeting
Cristina Has
08:55 | CURRENT DILEMMAS – A CONGRESS DEBATE (The complexity of EB)
Chair: Jo-David Fine
EB as a systemic disease – implications for research
Johann Bauer

Modelling EB in the research environment
Leena Bruckner-Tuderman

Curative vs disease modifying strategies
Jakub Tolar

Open debate – how to focus research in EB; avoid being spread too thinly because of complexity; where and how to direct the research; is prioritisation possible or feasible
09:30 | COFFEE BREAK
10:00 | THE CHALLENGES OF EB SKIN
Chair: Peter Marinkovich
Wound healing mechanisms – macrophages
Sabine Eming

Immune function and bacterial challenge
Josefine Hirschfeld

Clinical research
Maria Jose Escamez

Learnings from other diseases (cell inflammation)
David Abraham

Panel discussion
11:05 | INFLAMMATION, FIBROSIS, & THERAPEUTICS
Chair: Leena Bruckner-Tuderman
Fibrosis in EB – mechanisms and anti-fibrotic strategies
Alexander Nyström

Losartan for RDEB trial – results and international perspectives
Dimitra Kiritsi

miRNA in EB
Giovanna Zambruno

Panel discussion

Oral presentations

112 - Esteban Chacon-Solano
Novel players in the establishment and progression of fibrosis in recessive dystrophic epidermolysis bullosa

25 - Liat Samuelov
Skin microbiome characteristics of dystrophic epidermolysis bullosa patient
12:25 | LUNCH
13:25 | CANCER & CANCER THERAPEUTICS
Chair: Johann Bauer
KEYNOTE: Precision medicine for SCC
Kevin Harrington

Genetic overview/current RDEB knowledge
Andy South

Interdisciplinary management and therapies for EB associated cancers (skin, mucosal, internal)
Leena Bruckner-Tuderman

RDEB-SCC protocols (rigosertib, pembrolizumab, cetuximab, & nivolumab, SCC cream)
Jemima Mellerio

Panel discussion

Oral presentations

73 - Angela Filoni
Morphological and morphometrical analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a prospective study

128 - Jasbani Dayal
Heterogeneous addiction to TGFβ signalling in life threatening cutaneous squamous cell carcinomas arising in recessive dystrophic epidermolysis bullosa
15:10 | TEA BREAK
15:40 | THERAPEUTICS
Chair: Jouni Uitto
EBS target and treatment options/targeting EB as an inflammatory disease
Thomas Magin

Read-through therapeutics: drug re-purposing for EB patients
David Woodley

Topical treatments – an update
Dedee Murrell
16:20 | NATURAL HISTORY – IMPLICATIONS FOR CLINICAL TRIAL DESIGN
Chair: Jouni Uitto
PEBLES
Jemima Mellerio

The EB clinical characterisation and outcomes database
Anna Bruckner

Discussion
16:55 | CLOSE
Join Waitlist We will inform you when the product arrives in stock. Just leave your valid email address below.
Email Quantity We won't share your address with anybody else.
X
//]]>